Over the next fifteen years, the biopharmaceutical industry faces a wave of change across research, manufacturing, commercial strategy, and regulation. Advances in AI and machine learning are reshaping how drugs are discovered, while personalized medicine, decentralized trials, and sustainable production are moving from pilot projects toward standard practice.
In this webinar, Anantharaman K V draws on more than 25 years in healthcare and life sciences market research to unpack these shifts, from the industry's move away from blockbuster drugs toward diversified, value-based therapies, to the growing influence of emerging markets and closer alignment between the FDA and EMA.
Ananth is Research Director for Healthcare & Life Sciences at Frost & Sullivan, where he leads market research, strategic advisory, and competitive intelligence work, including syndicated research, KOL analytics, and procurement and sourcing studies for organizations across the sector.
In this webinar, you will hear about:
- How AI, machine learning, and advanced diagnostics are transforming drug discovery
- The shift from blockbuster drugs to diversified, value-based therapies
- What decentralized trials and sustainable manufacturing mean for the industry
- The regulatory and market impact of emerging players, particularly China, and closer FDA/EMA alignment
This webinar is hosted by SPARK TEL AVIV as part of the SPARK Europe Education Webinar Series, running every month on a Wednesday at 16:00 CET.